Table 2 Univariate analysis of potential risk factors for HBV reactivation in HBsAg-negative DLBCL patients

Total

159

6

HBcAb

0.001

 –

110 (69.2)

0 (0)

 +

49 (30.8)

6 (100.0)

Age (years)

0.237

 ≤60

65 (40.9)

4 (66.7)

 >60

94 (59.1)

2 (33.3)

Sex

1.000

 Female

66 (41.5)

2 (33.3)

 Male

93 (58.5)

4 (66.7)

ECOG PS

1.000

 0–1

137 (86.2)

5 (83.3)

 ≥2

22 (13.8)

1 (16.7)

Bulky mass

0.343

 Yes

115 (72.3)

6 (100.0)

 No

44 (27.7)

0 (0)

B symptoms

1.000

 –

118 (74.2)

5 (83.3)

 +

41 (25.8)

1 (16.7)

Ann Arbor stage^†

0.211

 I–II

79 (49.7)

1 (16.7)

 III-IV

79 (49.7)

5 (83.3)

Liver involvement

1.000

 –

151 (95.0)

6 (100.0)

 +

8 (5.0)

0 (0)

Spleen involvement

0.441

 –

145 (91.2)

5 (83.3)

 +

14 (8.8)

1 (16.7)

Involved extranodal sites

0.627

 <2

122 (76.7)

4 (66.7)

 ≥2

37 (23.3)

2 (33.3)

Bone marrow involvement

1.000

 –

148 (93.1)

6 (100.0)

 +

11 (6.9)

0 (0)

IPI score^†

0.402

 0–1

68 (42.8)

1 (16.7)

 2–5

90 (56.6)

5 (83.3)

HBeAb

0.094

 –

146 (91.8)

4 (66.7)

 +

13 (8.2)

2 (33.3)

ALT

0.597

 ≤40 U/L

136 (85.5)

6 (100.0)

 >40 U/L

23 (14.5)

0 (0)

AST

0.526

 ≤45 U/L

141 (88.7)

5 (83.3)

 >45 U/L

18 (11.3)

1 (16.7)

TB

0.463

 ≤20.5 μmol/L

144 (90.6)

5 (83.3)

 >20.5 μmol/L

15 (9.4)

1 (16.7)

LDH

0.681

 ≤245 U/mL

97 (61.0)

3 (50.0)

 >245 U/mL

62 (39.0)

3 (50.0)